This project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 823282

The gene therapy explorer

The initial discovery
CombiGene’ originated in the 1990s, when the company’s scientific founders, Professor Merab Kokaia and Associate Professor David Woldbye, demonstrated that neuropeptide Y (NPY) inhibits epileptic seizures in animals and that a more pronounced anti-seizure effect is achieved if NPY is combined with an increased level of the NPY receptor Y2.
The great challenge at that time was that there was no adequate means of applying the knowledge of NPY and the Y2 receptor to create an effective treatment, since there was no way of administering the possible treatment to humans.

Decisive discovery
The discovery that a safe, non-pathogenic virus whose own DNA was largely removed and replaced with functional DNA sequences (so-called AAV vectors) can be used to “transport” gene-therapeutic drugs suddenly presented entirely new possibilities for Professor Kokaia and Associate Professor Woldbye.

In April 2006, entrepreneur and financier Lars Thunberg, together with Merab Kokaia and David Woldbye, formed CombiGene AB to create a platform for further development and commercialization of the scientific discoveries.

CombiGene as a listed company
On 25 May 2015 CombiGene was listed as a public company on SPOTLIGHT Stock Market (then AktieTorget). The listing generated 12.5 million kronor in research capital and, in 2016, a strong financial position enabled CombiGene to test the final candidate drug, named CG01.

During 2017 and 2018 CombiGene carried out several preclinical studies with CG01. All studies confirmed the anti-epileptic effects of CG01 and during 2018 CombiGene began extensive preparations for clinical studies, i.e., human trials.

Since the listing in May, CombiGene has carried out 6 new issues that have raised 48 million kronor in research and development capital. During 2018 CombiGene was also awarded €3.36 million from Horizon 2020 (the EU framework programme for research and innovation) for the ongoing development of CG01.

The gene therapy explorer
During the development of CG01, CombiGene has amassed a knowledge of gene therapy that is unique among Swedish companies. Concurrently, the company has established a broad international contact network within the global pharmaceutical industry. CombiGene is now seeking additional interesting gene therapy projects in order to broaden the business to include treatments for more diseases for which gene therapy can play a decisive role in improving the quality of life for millions of sufferers.

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"